Elevara Medicines
elevara.com
Actively hiring
Biotechnology
Immunology & Inflammation Therapeutics
As featured in
Follow
Overview
News
Salaries
Products
People
Growth
Offices
Financials
Funding and backers
Total raised
$70M
1 round on record
Latest round
$70M
Series A · Oct 2025 · 11 mo ago
Backers
1
Sofinnova Partners
The money's age
Fresh money
11 months since the last round · not hiring
Momentum
35/100
in the news, fresh money
Last sign of life
this month
a posting or a news item
The story so fareach stage dated by its source: the company's releases, the press, registers, filings
Oct 21, 2025
Raised a round Series A $70M
Funding rounds
| Round | Date | Amount | Investors | Source |
|---|---|---|---|---|
| Series A | Oct 2025 | $70M | — | streetinsider.com |
Backed byfrom the funds' portfolios and accelerator catalogs
Sofinnova Partners Investors in similar startupsfunds that back the companies most like this one
Similar startupsby what they do, their industry and backers
Coultreon Biopharma is a clinical-stage biotech company developing next-generation precision medicines for immunology and autoimmune…
We believe that clinical remission should be the standard—not the exception—for treating chronic inflammatory diseases like COPD, asthma…
Pincelli is a pre-clinical stage biotech company focused on the development of innovative first-in-class treatments for rare skin diseases.
Quell Therapeutics is a clinical-stage company, fuelled by curiosity and discovery, on a mission to make life better for those battling…
A biotech company developing better medicines for patients with autoimmune and inflammatory diseases. Leveraging powerful insights into the…
CAMPfield Therapeutics is a clinical-stage biopharmaceutical company developing prifemilast, a once-daily oral PDE4B-selective inhibitor…
Overview
Elevara Medicines is a clinical-stage biotech. ELV001 targets fibroblast-like synoviocytes and synergizes with DMARDs to achieve clinical remission in RA.
News
Report
Elevara Medicines Doses First Patient in Phase 2b START-SYNERGY Trial of ELV001 in Rheumatoid Arthritis Patients with Incomplete Response to TNFi
ELV001 aiming to disrupt the treatment paradigm for patients with incomplete response to standard of care (methotrexate + TNF inhibitors)Phase 2b trial enrolling approximately 180 patients across nine countriesPrimary endpoint: change in DAS28-CRP at week
Read more
Report
Elevara Medicines Doses First Patient In Phase 2B START-SYNERGY Trial Of ELV001 In Rheumatoid Arthritis Patients With Incomplete Response To Tnfi
Read more
Report
Elevara Medicines Raises $70 Million Series A to Advance Phase 2 Rheumatoid Arthritis Trial and Expand Pipeline
Co-led by Forbion and Sofinnova Partners, along with founding investor Monograph Capital, and WeatherdenInnovative lead program, ELV001, in-licensed by Elevara from Japan's Teijin Pharma with good tolerability and safety, plus early signs of efficacy in P
Read more
Report
Financials
Total raised
$70M
Latest round
Series A
Funding rounds
1
Funding rounds
| Round | Announced | Amount | |
|---|---|---|---|
| Series A | 2025 | $70M | Details |